Allogeneic CAR T May Expand Access to Community-Based Treatment

In an interview with Targeted Oncology, Jeff Sharman, MD, SCRI at Willamette Valley Cancer Institute & Research Center, discusses how the use of allogeneic chimeric antigen receptor (CAR) T-cell therapy in the ALPHA3 study (NCT06500273) may help overcome many of the logistical barriers associated with autologous CAR T and broaden access to advanced cellular therapies in community oncology settings.

Watch part 1 and part 2 of Dr Sharman’s interview.

A notable aspect of the ALPHA3 study was the participation of both academic and community cancer centers, providing early insight into the practical feasibility of delivering allogeneic CAR T-cell therapy outside of specialized tertiary-care institutions.

According to Sharman, autologous CAR T-cell therapies remain challenging to implement in many community practices because of their complex manufacturing and administrative requirements. Treatment often depends on coordination with hospital partners, access to leukapheresis services, individualized cell manufacturing, and substantial operational infrastructure to navigate reimbursement processes and payer agreements. Financial considerations can be particularly significant for independent oncology practices, where the acquisition costs of cellular therapies may create additional risk and administrative burden.

Allogeneic CAR T therapy offers a markedly different model. Because the product is manufactured in advance and not derived from an individual patient’s cells, treatment can be administered without the delays and logistical challenges associated with leukapheresis and patient-specific manufacturing. This “off-the-shelf” approach may be especially valuable for patients who require timely intervention and for practices seeking a more streamlined cellular therapy workflow.

Sharman noted that administration within the ALPHA3 study was relatively straightforward. Participating sites received cryopreserved product, allowed it to thaw according to protocol, and infused it following standard lymphodepleting chemotherapy regimens familiar to most oncologists. The process did not require specialized manufacturing coordination or additional procedural steps typically associated with autologous CAR T-cell treatment.

Drawing on the experience of multiple community-based investigators within his network, Sharman reported that treatment was delivered successfully without major logistical barriers. Although questions regarding long-term cost, reimbursement, and broader implementation remain to be answered, the experience to date suggests that allogeneic CAR T-cell therapy could make advanced cellular immunotherapy more accessible across community oncology practices if ongoing clinical development proves successful.

Read the full interview here.